By Dr. Harriet Kamendi, PhD — Regulatory Toxicologist & CEO, Kandih BioScience
The New York Post reports a rising trend among heavy cannabis users:
“scromiting” — a mix of screaming and vomiting — formally known as Cannabinoid Hyperemesis Syndrome (CHS).
Patients suffer uncontrollable nausea, repetitive vomiting, abdominal pain, dehydration, and panic. Hospitalizations are increasing nationwide.
(New York Post, 2025)
This isn’t fringe or sensational.
It’s a modern toxicology case study in dose, duration, metabolism, and chronic exposure.
Cannabis may be “natural,” but toxicologists know this rule better than anyone:
Everything becomes toxic at the wrong dose, wrong duration, or wrong formulation.
What Is “Scromiting,” Really?
CHS happens after years of heavy use of high-THC products — especially vapes, oils, resins, and edibles.
And here’s the toxicology paradox:
Low-dose THC can reduce nausea.
Chronic, high-dose THC can cause extreme vomiting.
This flip is exactly why toxicology matters.
Mechanistically, CHS shows us:
Dose + duration determine toxicity
Chronic THC overstimulates CB1 receptors in the brain and gut → disrupting digestion and vomiting control.
Route of exposure matters
Edibles and oils create:
delayed onset
prolonged blood levels
metabolite buildup
This sustained exposure profile is a classic toxicokinetic driver of adverse events.
Formulation innovation without safety innovation = risk
Highly potent concentrates (“dabs,” oils, distillates) didn’t come with:
chronic toxicity studies
receptor desensitization assessments
exposure limits
cumulative risk evaluations
This is exactly how industries create unexpected emergencies.
Why Toxicologists Care: CHS Is an Exposure Science Problem
CHS sits at the intersection of pharmacology, exposure science, and toxicology:
Chronic exposure
Daily use transforms THC from therapeutic to toxic.
Bioaccumulation
Persistent metabolites irritate CB1-rich tissues.
Receptor dysregulation
Repeated overstimulation → receptor burnout → paradoxical vomiting.
Population vulnerability
Young adults, heavy daily users, and high-THC product consumers carry the highest risk.
This is exactly the type of scenario toxicologists are trained to predict — but weren’t at the table to prevent.
Regulatory Toxicology & Product Development Implications
1. The toxicology gap in cannabis regulation
Cannabis products generally avoid:
mandatory long-term safety studies
standardized toxicokinetic evaluations
chronic exposure assessments
metabolite toxicity mapping
This leaves major safety blind spots.
2. Product developers must design for exposure, not hype
High-potency formulations need:
defined maximum daily THC limits
bioavailability-adjusted serving sizes
chronic-use warnings
validated PK/PD and TK data
Developing for experience instead of exposure is a recipe for toxicity.
3. Clinical toxicology must integrate surveillance
There is no FAERS-equivalent for cannabis adverse events.
That means:
under-reporting
delayed recognition
reactive—not preventive—responses
Toxicologists should lead cannabis toxicovigilance frameworks.
My Professional Opinion: “Natural” Is Not a Free Pass
As a toxicologist, CHS looks less like a mystery and more like a predictable failure of safety-by-design.
The cannabis industry optimized:
potency
bioavailability
flavor
convenience
…but never optimized long-term safety.
Consumers translated “plant-based” into “risk-free.”
Companies translated “market demand” into “dose escalation.”
My stance:
Cannabis now needs the same toxicology rigor as pharmaceuticals.
Not because it’s dangerous — but because any biologically active compound used daily becomes a toxicology problem.
That means:
establishing NOAELs and chronic-exposure thresholds
mapping metabolism-based risks
enforcing real labeling standards
educating consumers about dose and duration
tracking adverse-event data
designing formulations with safety margins
Products should not be engineered for maximum potency without matching safety architecture.
The Bottom Line
“Scromiting” isn’t a punchline — it’s a public-health warning.
It shows us:
“natural” ≠ non-toxic
chronic exposure creates new harms
formulation changes create new risks
toxicology must guide cannabis innovation, not chase it
For developers, regulators, clinicians, and dispensaries, the message is clear:
Toxicology isn’t optional. It is your risk management strategy.
Failing to integrate it early is how industries lose trust — and how consumers get hurt.
References (with Links)
1. New York Post
New health concern linked to chronic cannabis use: “scromiting.”
Published Nov 29, 2025.
https://nypost.com/2025/11/29/health/new-health-concern-linked-to-chronic-cannabis-use
2. U.S. Food and Drug Administration (FDA)
Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cannabis-and-cannabis-derived-compounds-quality-considerations-clinical-research-guidance-industry
3. Centers for Disease Control and Prevention (CDC)
Health Effects of Marijuana: What You Need to Know
https://www.cdc.gov/cannabis/health-effects/index.html
4. Simonetto DA, et al.
Cannabinoid Hyperemesis: A Case Series of 98 Patients. Mayo Clinic Proceedings (2012).
https://www.mayoclinicproceedings.org/article/S0025-6196(11)00026-7/fulltext
5. Sorensen CJ, et al.
Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment — A Review. Journal of Medical Toxicology (2020).
https://link.springer.com/article/10.1007/s13181-016-0595-z